|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MED20 |
Gene summary for MED20 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MED20 | Gene ID | 9477 |
| Gene name | mediator complex subunit 20 | |
| Gene Alias | PRO0213 | |
| Cytomap | 6p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B3KUJ9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9477 | MED20 | LZE2T | Human | Esophagus | ESCC | 1.80e-04 | 6.79e-01 | 0.082 |
| 9477 | MED20 | LZE4T | Human | Esophagus | ESCC | 1.35e-04 | 1.87e-01 | 0.0811 |
| 9477 | MED20 | LZE7T | Human | Esophagus | ESCC | 1.93e-02 | 1.61e-01 | 0.0667 |
| 9477 | MED20 | LZE8T | Human | Esophagus | ESCC | 3.47e-02 | 1.17e-01 | 0.067 |
| 9477 | MED20 | LZE20T | Human | Esophagus | ESCC | 6.22e-05 | 1.60e-01 | 0.0662 |
| 9477 | MED20 | LZE24T | Human | Esophagus | ESCC | 7.09e-07 | 2.17e-01 | 0.0596 |
| 9477 | MED20 | LZE6T | Human | Esophagus | ESCC | 3.89e-03 | 2.20e-01 | 0.0845 |
| 9477 | MED20 | P2T-E | Human | Esophagus | ESCC | 1.59e-13 | 2.62e-01 | 0.1177 |
| 9477 | MED20 | P4T-E | Human | Esophagus | ESCC | 9.03e-12 | 3.36e-01 | 0.1323 |
| 9477 | MED20 | P5T-E | Human | Esophagus | ESCC | 4.33e-09 | 1.63e-01 | 0.1327 |
| 9477 | MED20 | P8T-E | Human | Esophagus | ESCC | 2.90e-04 | 1.08e-01 | 0.0889 |
| 9477 | MED20 | P9T-E | Human | Esophagus | ESCC | 1.59e-02 | 1.40e-01 | 0.1131 |
| 9477 | MED20 | P10T-E | Human | Esophagus | ESCC | 2.04e-14 | 2.35e-01 | 0.116 |
| 9477 | MED20 | P11T-E | Human | Esophagus | ESCC | 1.77e-06 | 3.06e-01 | 0.1426 |
| 9477 | MED20 | P12T-E | Human | Esophagus | ESCC | 3.18e-13 | 2.54e-01 | 0.1122 |
| 9477 | MED20 | P15T-E | Human | Esophagus | ESCC | 2.21e-09 | 2.04e-01 | 0.1149 |
| 9477 | MED20 | P16T-E | Human | Esophagus | ESCC | 1.90e-18 | 3.50e-01 | 0.1153 |
| 9477 | MED20 | P17T-E | Human | Esophagus | ESCC | 4.36e-08 | 2.54e-01 | 0.1278 |
| 9477 | MED20 | P19T-E | Human | Esophagus | ESCC | 4.67e-09 | 5.56e-01 | 0.1662 |
| 9477 | MED20 | P20T-E | Human | Esophagus | ESCC | 2.56e-06 | 1.43e-01 | 0.1124 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MED20 | SNV | Missense_Mutation | c.458G>A | p.Cys153Tyr | p.C153Y | Q9H944 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AR-A24Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MED20 | insertion | Nonsense_Mutation | novel | c.455_456insATGCTTTTGGCTGTTATTTTGCAGTTAATACCTTGGGCATGTAGGACCCAGT | p.Asp152GlufsTer10 | p.D152Efs*10 | Q9H944 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| MED20 | insertion | Nonsense_Mutation | novel | c.463_464insAGCTCAGTTCAGTACCATAACTAA | p.Trp154_Ser155insLysLeuSerSerValProTerLeu | p.W154_S155insKLSSVP*L | Q9H944 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| MED20 | insertion | Frame_Shift_Ins | novel | c.406_407insATTTGCTCTCGTCCAGGTTTATTTATTTGTATTTTTCTGTA | p.Arg136HisfsTer28 | p.R136Hfs*28 | Q9H944 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| MED20 | insertion | In_Frame_Ins | novel | c.222_223insCAT | p.Ser74_Cys75insHis | p.S74_C75insH | Q9H944 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| MED20 | insertion | Frame_Shift_Ins | novel | c.220_221insTCTCGGCTCACTGCAAGCTCTGCCTCCCGGGTTTA | p.Ser74IlefsTer35 | p.S74Ifs*35 | Q9H944 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| MED20 | SNV | Missense_Mutation | rs747406107 | c.37N>A | p.Glu13Lys | p.E13K | Q9H944 | protein_coding | deleterious(0.04) | probably_damaging(0.936) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MED20 | SNV | Missense_Mutation | novel | c.602N>A | p.Arg201His | p.R201H | Q9H944 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MED20 | SNV | Missense_Mutation | novel | c.19N>C | p.Ser7Pro | p.S7P | Q9H944 | protein_coding | tolerated(0.2) | possibly_damaging(0.609) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MED20 | SNV | Missense_Mutation | novel | c.91N>T | p.Leu31Phe | p.L31F | Q9H944 | protein_coding | deleterious(0) | probably_damaging(0.913) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |